Boehringer pushes survodutide into MASH after 13% weight loss in NEJM trial
SYNCHRONIZE-1 also cut liver fat by up to 63.1%, and the Phase 3 LIVERAGE program targets adults with MASH and fibrosis.
MH
By Maren Holt · Senior Reporter, GLP-1
Jun 11 03:00 ETSource: drugdiscoverytrends.com
The wire
- 01The 76-week Phase 3 SYNCHRONIZE-1 trial, published June 7 in the New England Journal of Medicine, found 6.0 mg survodutide produced 13.0% mean weight loss versus 5.4% for placebo across 725 adults with obesity.
- 02The glucagon/GLP-1 dual agonist targets a liver indication where Rezdiffra and Wegovy hold the only approvals, giving clinicians a possible third option for MASH with fibrosis.
- 03Liver-fat data, including roughly 6 in 10 patients normalising in SYNCHRONIZE-MASLD at 48 weeks, are imaging endpoints; the company says LIVERAGE outcomes are still years away.
From the source
Read at drugdiscoverytrends.comBoehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
“We have a program in MASH, in the liver, the LIVERAGE program , plus a robust data-generation program to come over the next couple of years, because we want to bring a comprehensive package for metabolic health,” said Neeraja Balachander, who oversees the company’s cardio-renal-metabolic portfolio. LIVERAGE is Boehringer’s Phase 3 program in adults with MASH and fibrosis.